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Experimental evidence for the beneficial effects on heart failure of chronic treatment with ACE inhibitors accumulated from early
1980 in experimental models of LV dysfunction secondary to AMI. These studies demonstrated an improvement in
hemodynamics, LV remodeling,     and mortality with ACE inhibitor treatment.   The effect of ACE inhibitors during the acute
phase of AMI was less clear, although there was evidence of protection from ischemic damage, possibly mediated by an
increase in collateral coronary blood flow.     
Clinical Data
The striking beneficial results of prolonged ACE inhibitor therapy in the CONSENSUS-I trial  on mortality of patients with
advanced CHF have been followed by a series of trials in patients with less severe heart failure or asymptomatic LV dysfunction
of any origin    or limited to AMI.    Consistent with the experimental data, the latter studies showed that ACE inhibition
clearly produces favorable effects on mortality and LV function in selected high-risk post-AMI populations. More recent trials
have addressed the role of ACE inhibition in relatively unselected patients     or in those with anterior AMI   in whom
treatment was initiated during the first day of AMI. Overall, these trials indicate a small but definite benefit of about 5 lives saved
for every 1000 patients treated (Table 1⇓).
Table 1.
Overview of ACE Inhibitor Trials on Patients With AMI
Trial Patients Treated With ACE
Inhibitors (%)
Control Subjects,
deaths/treated (%)
Agent, deaths/treated
(%)
11 small trials 150/2175 153/2119 Various
(6.9) (7.2)
CONSENSUS-
II
219/3044 192/3046 Enalapril, IV and oral
(7.2) (6.3)
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Trial Patients Treated With ACE
Inhibitors (%)
Control Subjects,
deaths/treated (%)
Agent, deaths/treated
(%)
GISSI-3 597/9435 673/9460 Lisinopril, oral
(6.3) (7.1)
ISIS-4 2088/29 028 2231/29 022 Captopril, oral
(7.2) (7.7)
CCS-1 617/6814 654/6820 Captopril, oral
(9.1) (9.6)
Overview 3671/50 496 3903/50 467 P=.006
(7.27) (7.73)
4.6 lives saved per 1000 treated patients. ACE inhibitors reduced mortality in all trials, except for CONSENSUS II, in
which 1-month mortality (reported in the table) was not significantly higher in enalapril-allocated patients. The plan for
this trial was to recruit 9000 patients, but the study was stopped after randomization of 6090 patients. In this trial, the
ACE inhibitor was administered in the first 24 hours after AMI by intravenous (IV) infusion (enalaprilat) and then orally
for 6 months.
Modified from Reference 21 with permission.
Table 2⇓⇓ summarizes the evidence available from the literature (the results of the TRACE  and SMILE  studies were not
available at the time of the meeting but are included for completeness, and their findings confirm previous evidence). Table 2⇓
and Fig 1⇓ summarize the background information: a decrease in the relative size of the beneficial effects is associated with a
broadening of the population who might derive a clinically relevant benefit. Although the results of these trials are
complementary in many ways, they also are a potential source of contradictory interpretation.       For example, are
the populations randomized in CONSENSUS II,  GISSI-3,  and ISIS-4  concordant or discordant with respect to those of the
other trials? Although ongoing trials  are addressing the issue of long-term secondary prevention with ACE inhibitors in patients
at high risk of vascular events, no other placebo-controlled trials in the acute phase of AMI are planned. Thus, there is a need to
translate the available evidence into reasonable and coherent recommendations for the use of ACE inhibitors in AMI and post-
AMI patients.
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Figure 1.
Chart showing randomized clinical trials on ACE inhibitors from CHF to coronary artery disease. Length of each bar
represents the time span from the first to the last patient enrolled in each trial. LVD indicates left ventricular dysfunction;
CAD, coronary artery disease.
Table 2.
Summary of Randomized Clinical Trials
Randomized Clinical Trials of ACE Inhibitors in Heart Failure Randomized Clinical Trials 
Inhibitors in High-Risk AMI
CONSENSUS-
I
SOLVD
Treatment
V-HeFT II SOLVD
Prevention
SAVE AIRE T
Randomization, y April 1985-
December
1986
June
1986-
March
1989
March
1986-
September
1990
July 1986-
May 1990
January
1987-
January
1990
April
1991-
August
1992
J
A
1
Patients randomized, n 253 2569 804 4228 2231 2006 1
Patients screened … 39 924 2741 . . . 36 630 30 717 7
Randomized/screened,
%
6 6.5 2

1
Randomized Clinical Trials of ACE Inhibitors in Heart Failure Randomized Clinical Trials 
Inhibitors in High-Risk AMI
Population NYHA IV
(CAD, 73%;
previous MI
47%)
NYHA II-
III, EF
≤35%
(CAD
71%;
previous
MI, 66%)
NYHA II-
III, EF
<45%
(CAD,
54%;
previous
MI, 47%)
NYHA I-II,
EF ≤35%
(CAD,
83%;
previous
MI, 80%)
MI, EF
≤40%
MI,
clinical
HF
M
≤
Exclusion criteria APE, MI<2
mo, Cr>300
μmol/L
NYHA IV,
MI≤1 mo,
age>80 y,
Cr>177
μmol/L
MI<90 d Clinical
HF, MI≤1
mo,
age>80 y,
Cr>177
μmol/L
ACE
inhibitor
for CHF
or HBP,
age>80
y,
Cr>221
μmol/L
NYHA
IV,
clinical
severe
RF
0
t
n
t
C
μ
Drug initiation from MI >60 d >30 d >90 d >30 d 3-16 d
(mean,
11 d)
3-10 d
(mean,
5.4 d)
3
(
d
Drug and dose, mg Enalapril, 5 to
20 bid
Enalapril,
2.5 to 10
bid
Enalapril 5
to 20 daily
Enalapril,
2.5 to 10
bid
Captopril,
12.5 to
50 tid
Ramipril,
2.5 to 5
bid
T
1
Follow-up duration 1 d-20 mo
(mean, 188
mo)
22-55 mo
(mean,
41.4 mo)
6-68 mo
(mean, 30
mo)
14.6-62
mo (mean,
37.4 mo)
24-60 mo
(mean,
42 mo)
6-30 mo
(mean,
15 mo)
2
Overall mortality, %
Control 54 39.7 38.2 15.8 24.6 23 6
Treated 39 35.2 32.8 14.8 20.4 17 3
Reduction, % 27 16 11.1 8 19 27 1
P .003 .0036 .08 .30 .019 .002 .
Lives saved per 1000
patients per month
23.6 1.1 1.7 . . . 1.0 3.5 2
Needed to be treated
to save 1 life, n
7 22 19 . . . 24 17 1
1
3
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CATS indicates Captopril and Thrombolysis Study; NYHA, New York Heart Association class; HF, heart failure; WMI,
wall motion index; EF, ejection fraction; CAD, coronary artery disease; APE, acute pulmonary edema; Cr, serum
creatinine; HBP, high blood pressure; RF, renal failure; and SBP, systolic blood pressure.
1 Figures are not comparable with post-AMI trials because of different screening procedures.
2 Hydralazine plus isosorbide dinitrate.
3 The figures should be compared with caution between studies of different durations.
Table 2B.
Continued
Randomized Clinical Trials of ACE Inhibitors in High-Risk
AMI Patients
Randomized Clinical Trials of ACE Inhibitors in
Relatively Unselected AMI Patients
SMILE CATS CONSENSUS-II GISSI-3 ISIS-4 CCS-1
January 1991-
December 1992
April 1990-
December
1991
March 1990- March
1991
June 1991- July
1993
July
1991-
August
1993
January 1990-
April 1995
1556 298 6090 19 394 58 050 13 634
20 261 … 10 387 43 047 … …
8 … 59 45 … …
Anterior MI,
nonthrombolyzed
Anterior MI,
thrombolyzed
MI MI MI MI
SBP<100 mm Hg,
Killip 4, Cr>186
μmol/L
BP≤100/55
mm Hg, RF
BP<100/60, >105/65
mm Hg, clinical
severe RF
Killip 4, SBP<100
mm Hg, Cr>177
μmol/L
SBP <90-
100, Killip
4
SBP<90 mm
Hg, chronic
diuretic
6-24 h (mean, 15 h) ≤6 h ≤1 d ≤1 d ≤1 d ≤36 h
Zofenopril, 7.5 to 30
bid
Captopril,
6.25 to 25 bid
Enalaprilat IV, po 5 to
20 bid
Lisinopril, 2.5 to
10 once daily
Captopril,
6.25 to
50 bid
Captopril, 6.25
to 12.5 tid
Randomized Clinical Trials of ACE Inhibitors in High-Risk
AMI Patients
Randomized Clinical Trials of ACE Inhibitors in
Relatively Unselected AMI Patients
12 mo 3 mo 41-180 d (mean, 6
mo; 2952 patients)
42 d 1 mo 4 weeks
6.5 4.0 9.4 7.1 7.7 9.6
4.9 6.0 10.2 6.3 7.2 9.1
24 … … 11 7.0 6.0
.198 .03 .02 0.3
11.2 0 0 5.4 4.9 5.3
63 … … 125 200 200
To address these issues, a meeting of investigators actively involved in the principal published ACE inhibitor trials was convened
to reach a consensus on ACE inhibitor use in patients with AMI.
Methods and Participants
The GISSI group invited the coordinating groups and/or principal investigators of the CONSENSUS, AIRE, SAVE, SOLVD, ISIS-
4, GISSI-3, and V-HeFT trials. A few other experts were invited, to provide a wide range of opinions, and representatives of
collaborative research groups from Latin America participated, to allow discussion of the problems of transferability and
relevance in different health care settings.
The meeting was held in Berlin during the XII World Congress of Cardiology and the XVI Congress of the European Society of
Cardiology, September 10, 1994. The members of the panel are listed in the “Appendix.”
A summary of the existing data from the randomized clinical trials of ACE inhibitors in AMI was sent to all participants 1 month
before the meeting to allow proper consideration and to avoid repetitive presentations. Confidential unpublished data from the
GISSI-3, ISIS-4, and CCS-1 trials were also included.
The following questions were submitted to the panel at the same time to facilitate a productive and practice-oriented debate.
1. Is the primary indication for ACE inhibitor the treatment of the patients with AMI syndrome or with LV dysfunction that at any
time complicates AMI? In the first case, should all patients or only those at higher risk be treated (ie, anterior AMI, large AMI)?
2. When should ACE inhibitor treatment be started?
3. What are the criteria of initial exclusion and subsequent withdrawal or continuation of ACE -inhibitor treatment of AMI
patients?
4. Do known or suggested pathophysiological mechanisms provide a satisfactory explanation of the observed clinical effects of
ACE inhibitor therapy?
Summary of Panel Discussion and Conclusions
Questions 1 and 2
Is primary indication for ACE inhibitor the treatment of the patients with AMI syndrome or with LV dysfunction that at any time
complicates AMI? In the first case, should all patients or only those at higher risk be treated (ie, anterior AMI, large AMI)?
When should ACE inhibitor treatment be started?
The two questions are presented together because the answer to question 1 is integrally related to question 2. The evidence
available from the trials on ACE inhibitors is documented in detail in Tables 1⇑ and 2⇑ and may be summarized as follows.
Treatment with ACE inhibitors has a beneficial effect in patients selected for the presence of LV dysfunction after AMI and in
relatively unselected patients presenting with AMI. The benefit increases in patients with clinical or laboratory evidence of LV
dysfunction. There is still uncertainty about treating all AMI patients without contraindications to ACE inhibitors or targeting a
selected higher-risk group.
The extension of the indication of early treatment to an unselected AMI population is supported by the consideration of the
following. In the absence of absolute predictive criteria, short-term treatment is likely to offer protection from LV dysfunction to
many patients before they develop it. There is evidence in the GISSI-3 and ISIS-4 trials of a very early benefit (Fig 2⇓) when
reliable, objective measurement of LV dysfunction may be impractical. A beneficial effect of ACE inhibitor treatment in GISSI-3
and ISIS-4 is observed across a wide range of patients, although as expected the benefit was less in patients at lower risk. For
example, the GISSI-3 results show that 33 patients with an impaired hemodynamic state at entry (Killip class >1) had to be
treated for 1 life to be saved; 333 patients without complications (Killip class 1) had to be treated for 1 life to be saved.
Nevertheless, the number of lives saved in the group of lower-risk patients is important in absolute terms because of the greater
prevalence of this group of patients (ie, 24 lives saved in Killip class 1 versus 39 in Killip class >1 in GISSI-3). The potential risk
of an ACE inhibitor therapy started early after AMI is small and does not obscure its net benefit, as shown by GISSI-3 results:
persistent hypotension and renal dysfunction were significantly more common among lisinopril-treated patients than among
control subjects (Fig 3⇓), and most of the cases of persistent hypotension (>80%) and more than half of those of renal
dysfunction occurred within 7 days of randomization. However, a subsidiary analysis of GISSI-3 and ISIS-4 showed that in the
same period (days 0 through 7) mortality was lower in the ACE inhibitor–allocated patients (Fig 2⇓).
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Figure 2.
Bar graphs showing that in GISSI-3 and ISIS-4 ACE inhibitors saved lives during the very early phases. A, In the GISSI-3
lisinopril-allocated patients (cross-hatched bar), there were 76 fewer deaths than in the control-allocated group (open bar):
21 fewer for days 0 through 1, 43 fewer for days 2 through 7, and 12 fewer for the following days of treatment. B, In the
ISIS-4 captopril-allocated patients (cross-hatched bar), there were 143 fewer deaths than in the control-allocated group
(open bar): 44 fewer for days 0 through 1, 37 fewer for days 2 through 7; and 62 fewer for the following days of treatment.
Absolute reductions and percent contribution to total benefit are shown for each time interval.

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Figure 3.
Bar graphs showing that in GISSI-3 persistent hypotension (A) occurred chiefly during the acute phase of AMI, with >80%
of the cases occurring within day 2 from randomization, while excessive renal dysfunction (B; clinically defined by attending
cardiologists) occurred throughout the hospitalization. These two events were consistently more frequent in patients treated
with lisinopril (patterned bar) than in control subjects (open bar). Absolute increase of events and percent contribution to
total increase are shown for each time interval. Data on timing of the event are missing for 12 patients with persistent
hypotension and 1 with renal dysfunction.
In conclusion, evidence of an early benefit in unselected AMI patients was considered complementary to the favorable effects in
patients with LV dysfunction by some members of the panel but disputed by others. All agreed that patients with a clinically large
AMI and/or current or previous LV failure should certainly be considered for early treatment with an ACE inhibitor in the absence
of contraindications (eg, hypotension).
Question 3
What are the criteria for initial exclusion and subsequent withdrawal or continuation of ACE inhibitor treatment of AMI patients?
Exclusion Criteria
The safety profile of patients treated within 24 hours from the onset of symptoms appears acceptable if the following exclusion
criteria are applied: high risk of further serious hemodynamic deterioration (systolic blood pressure ≤100 mm Hg) and specific
contraindications (history of clinically relevant renal failure, history of bilateral stenosis of the renal arteries, or documented
allergy to ACE inhibitors).

Patients with low systolic blood pressure (100 to 110 mm Hg) in the first 24 hours after the onset of symptoms should be
monitored carefully.
No specific additional risk was shown in GISSI-3 or ISIS-4 for elderly patients or women, so ACE inhibitors are not
contraindicated in these populations.
Withdrawal or Continuation
The consistency of data on the role of ACE inhibitors from trials in patients with LV dysfunction or heart failure complicating AMI
(as in the AIRE, SAVE, and TRACE studies) strongly indicates that ACE inhibitors should be given to these patients. For this
reason, if at any time after AMI clinical signs and/or symptoms of LV dysfunction occur or are diagnosed instrumentally,
treatment should be continued over a long period of time. In other words, as soon as a patient becomes an “AIRE- or SAVE-like
patient,” he or she should be treated according to the indications of these studies (this recommendation was applied in the
GISSI-3 and ISIS-4 trials).
On the other hand, if a patient does not show signs or symptoms of LV dysfunction, it is likely that treatment can be stopped
safely after 4 to 6 weeks (based on existing evidence from GISSI-3 and ISIS-4). In this case, the patients should ideally be
reevaluated after a reasonable period (ie, 4 to 6 months) to check for evidence of LV function. The appearance of persistent
hypotension or clinically relevant renal dysfunction should be considered an indication for ACE inhibitor dose reduction or
withdrawal (at least temporarily).
Question 4
Do the suggested pathophysiological mechanisms provide a satisfactory explanation of ACE inhibitor clinical effects?
Even if randomized clinical trials alone cannot provide answers on specific pathophysiological mechanisms, the results of ACE
inhibitor trials in patients with LV dysfunction do appear to fit the remodeling hypothesis based on experimental studies and
represent a good example of the consistency of a mechanistic hypothesis with the clinical data. The exploratory analysis of echo
data from GISSI-3  supports this hypothesis in a large, relatively unselected population of patients treated very early after AMI.
Although the changes observed in LV volumes are small, they are statistically and clinically significant, as already shown in a
subgroup of patients from the SAVE trial.  A small decrease in LV volume in the whole population is consistent with a reduction
in the incidence of LV dysfunction.
Post hoc analyses of randomized clinical trials suggest that additional mechanisms (vasodilator and neurohormonal effects), in
addition to the effect on long-term remodeling, might contribute substantially to the favorable effect of ACE inhibitors. This is
suggested by the early beneficial effects (days 0 through 7, Fig 2⇑) documented in GISSI-3 and ISIS-4 and the reduced number
of ischemic events reported by the SOLVD and SAVE trials after long-term ACE inhibition (although as expected no evidence of
such an effect has been found with the short-term treatments in GISSI-3 and ISIS-4).
In particular, activation of the renin-angiotensin system in the first few days after AMI  may increase heart rate and systemic
vascular resistance and decrease coronary artery perfusion,  which may lead to infarct expansion. The early benefit observed
in GISSI-3, ISIS-4, and CSI-1 could be explained in this way.
Summary Statements
1. Patients with signs or symptoms of LV dysfunction at any time after AMI warrant prompt initiation of long-term (lifelong?) ACE
inhibitor treatment unless contraindications exist.
2. Treatment of AMI patients with ACE inhibitors may be started the first day after timely and careful observation of their
hemodynamic and clinical status and after administration of routinely recommended treatments (thrombolysis, aspirin, and β-
blockers). No absolute “efficacy” criteria currently are available to recommend selection of preferential subgroups in the early
phase of AMI.
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3. Within the time frame of 24 hours after AMI, there is no evidence that in relatively unselected AMI patients early treatment
with ACE inhibitors provides more efficacy. However, because mortality is highest in the acute phase of AMI, treatment should
not be delayed unnecessarily.
4. Discontinuing ACE inhibitor treatment that was begun in the early phase of AMI should be considered in patients without
asymptomatic LV dysfunction after 4 to 6 weeks. Further reassessment of LV function might be considered 4 to 6 months after
AMI.
5. The dose of an ACE inhibitor can be individualized on the basis of safety criteria (eg, hemodynamic response) because
simple criteria of efficacy, especially in the early phase, are not available. However, the target dose should be that used in the
clinical trials.
6. A planned meta-analysis of existing trials should allow more reliable focusing on predefined subgroups of patients at higher
risk of side effects or with better-defined profiles of potential benefit.
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